Skip to content



Researchers across Mass General Brigham hospitals support a multitude of cancer programs that explore cancer at the molecular, cellular, tissue, and whole-organism levels to advance the treatment and prevention of human disease.

Some of the key areas at Mass General Brigham include state-of-the-art and emerging approaches to diagnose, treat and manage cancer—including early cancer detection and prevention; precision medicine and evolving models of care; immunological therapies; combination therapies to circumvent resistance; methods to find and develop new targets and new drugs as well as new informatics-driven tools and research approaches

In addition, this sector works with the Pathology departments to explore the diagnosis and pathogenesis of disease, with a focus on cancer-related fields. Computational Pathology continues to be a primary focus at both hospitals. Industry collaborations across these fields are focused on drug discovery, stem cell research, and digital pathology, among others.

Cancer & Pathology Market Team


In the News

Proton beam cancer therapy ‘effective with fewer side effects’

February 1, 2016

A cancer treatment at the centre of an NHS controversy in 2014 causes fewer side effects in children than conventional radiotherapy, according to new research. The study, published in The Lancet Oncology, suggests proton beam therapy is as effective as other treatments. Researchers looked at 59 patients aged between three and 21 from 2003 to…

Can We Truly “Cure” Cancer?

January 28, 2016

Monica Bertagnolli, WMIF co-chair, chief of the Division of Surgical Oncology at Brigham and Women’s Hospital and chair of the Alliance for Clinical Trials in Oncology, a nationwide effort to test new therapies, speaks on Barack Obama’s aspirational plan in his final State of the Union to “cure cancer.”

Gary Ruvkun, PhD: MicroRNA, Cancer and Heart Disease

January 12, 2016

As a child growing up in the Sputnik era, Gary Ruvkun, PhD explored the night skies through the lens of a telescope and, as he learned more astronomy, realized with fascination that the universe has secret layers. “When you do visible astronomy, you see one set of stars. When you do X-ray as-tronomy, you see…

Study suggests that annual CA125 screening may reduce ovarian cancer deaths

January 8, 2016

Initial results from the world’s largest ovarian cancer screening trial suggest that tracking levels of a cancer-associated protein over time may help reduce ovarian cancer deaths by as much as 20 percent. Results of the 14-year study, led by investigators at University College London (UCL), are being published online in The Lancet. The U.K. Collaborative…

A Brigham and Women’s doctor is using tiny drones to target cancer

January 8, 2016

Drones are increasingly being used in innovative ways—from responding to train derailments to documenting fall foliage. They’ve even made it into the fight against cancer—though on a much, much smaller scale. Dr. Wilfred Ngwa, a medical physicist in radiation oncology at Brigham and Women’s Hospital, is working to apply drone technology to cancer treatment. Ngwa…

Colon Cancer: Virtual Colonoscopy Just As Effective, And Can Increase Screenings

January 8, 2016

Colon cancer is the third most common cancer diagnosed in men and women in the United States, according to American Cancer Society. Screenings are highly recommended for early detection, but many people dread these uncomfortable procedures which often involve inserting a tube in the rectum. New research published in JNCI: Journal of the National Cancer…

A lesson in love, faith and fighting

January 8, 2016

On Nov. 20, 2015, we lost one of our beloved warriors, Betty Lou Heath, but her story, unselfishly told to me by her beloved husband Kenneth, is a gift to all warriors that will live on. In 1997, Betty Lou Heath was working at Fairview Hospital in Great Barrington, Massachusetts. Talk about dedication: For 17…

Letters:Thanks to Powder Puff Team

January 8, 2016

Our family would like to express sincere thanks and gratitude to the Danvers High School Powder Puff Senior Girls Football Team for their generous contribution to the Adele McKinnon Fund for Breast Cancer Related Lymphedema Screening. The Danvers High senior girls opposed the Danvers High junior girls in the game played on Friday, Oct. 23.…

Love of Teaching Yields Potent New Drug Candidate, Major Acquisition

September 1, 2015

Mass General Brigham spin-off, Adheron, is acquired by Roche for $580 million. When pharmaceutical giant Roche announced plans to acquire Mass General Brigham spinoff Adheron Therapeutics in September, immunologist Michael Brenner, MD, couldn't help but recall the unlikely events that inspired the spinoff. The original spark that ignited Adheron's promising therapy for inflammatory and autoimmune…

Innovator Profile: Innovation's Building Blocks

April 1, 2015

A profile of Charles Serhan, PhD, DSc, a mastermind behind the inflammation pro-resolving therapies known as resolvins and the specialized pro-resolving mediators (SPM). Charles Serhan, PhD, DSc, a mastermind behind the inflammation pro-resolving therapies known as resolvins and the specialized pro-resolving mediators (SPM), is no stranger to the celebrity side of science. Coming of age…

Spinoff Profile: Raze Therapeutics

April 1, 2015

A look at the promising oncology therapeutics under exploration by Mass General Brigham spin-off, Raze Therapeutics. A new approach to treating certain cancers may lie in an often-overlooked corner of amino acid metabolism, according to the science behind a new Mass General Brigham spinoff. Promising oncology therapeutics under exploration by Raze Therapeutics aim to dismantle…

Novel Treatments for Kidney Diseases and Ovarian Cancer Therapy

December 1, 2014

A look into two of Innovation's Discovery Grant Profiles. Novel Treatments for Kidney Diseases Joseph Bonventre, MD, PhD BWH, RENAL Acute Kidney Injury is characterized by a rapid decline in kidney function and can be triggered by a number of insults. While AKI may resolve on its own or with care, the sequelae can include…

Fierce 15: Two Mass General Brigham Spinoffs Awarded Honors

December 1, 2014

Earlier this fall, Mass General Brigham spinoffs Editas Medicine and Spero received global recognition. Earlier this fall, Mass General Brigham spinoffs Editas Medicine and Spero received global recognition when they were named to the prestigious Fierce Biotech's Fierce 15, an annual compilation of leading biotech upstarts. Researchers around the globe are pursuing various strategies for…

Targeting Nanotechnology: BIND Therapeutics

August 1, 2014

A look into the targeted nanoparticle therapies known as Accurins—developed by BIND Therapeutics, the brainchild of Mass General Brigham innovator Omid Farokhzad, MD, and MIT legend Robert Langer, ScD. Cancer cells may give traditional chemotherapies short shrift, but the targeted nanoparticle therapies known as Accurins—developed by BIND Therapeutics, the brainchild of Mass General Brigham innovator…

CoStim's Novel Biologics Target Immune Checkpoint Inhibitors

December 1, 2013

Mass General Brigham spin-off, CoStim Pharmaceuticals, positioned to be a leader in the immune checkpoint regulation market. With excitement growing around immune checkpoint regulation as a major advance in treating cancer, the emergence of Mass General Brigham spin-off CoStim Pharmaceuticals could not be better timed. Industry experts expect the immune checkpoint therapy market will continue…